EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel rabies vaccine candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein

Lifang Shuai, Mingyu Xu, Nana Pei, Cheng Zhu, Marwa Belghait, Zhiming Hu, Jinlong Li, Hongwei Li, Yingying Mao, Hongyan Du iD

PLOS Neglected Tropical Diseases · 26.08.2025 · 19 (8) · e0013404

DOI: 10.1371/journal.pntd.0013404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 26.08.2025. Verfasst von Lifang Shuai und 9 weiteren Autor:innen. Beteiligte Einrichtung: South China Institute of Biomedicine, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Rabies Vaccines, Lentivirus, Rabies virus, Genetic Vectors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Natural Science Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rabies, caused by the rabies virus (RABV), remains a global public health issue. Traditional inactivated rabies vaccines are costly, risky, and require multiple doses for post-exposure prophylaxis. The rabies virus glycoprotein (RABV-G), essential for inducing protective antibodies, is crucial for new vaccine development. Lentiviral vectors offer promise due to their efficient gene delivery and strong immune responses. We designed three recombinant pseudotyped lentiviral vector vaccines with enhanced green fluorescent protein (eGFP) as marker, among VSV-G/LV-RABV-G the RABV-G only lies in the core of pseudotyped lentiviral particle, among RABV-G/LV-RABV-G the RABV-G lies in both of the core and the envelop and among RABV-G/LV-eGFP the RABV-G only lies in the envelop. These were tested for antigenicity, infectivity, and neutralizing antibody response. All vaccines showed strong antigen specificity and high titers for virus particles production. Immunization tests in mice showed that VSV-G/LV-RABV-G and RABV-G/LV-RABV-G vaccines induced high neutralizing antibody levels within 3 days, sustained up to 10 weeks. The RABV-G/LV-eGFP vaccine, especially with CPG-ODN adjuvant, also generated significant antibody responses. In summary, the recombinant pseudotyped lentiviral vector vaccines based on the RABV-G show promise for effective, single-dose rabies vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rabies VaccinesLentivirusRabies virusGenetic VectorsRabiesViral Envelope ProteinsGlycoproteinsAntigens, ViralVaccine DevelopmentAnimalsMiceAntibodies, ViralAntibodies, NeutralizingMice, Inbred BALB CFemaleVaccines, SyntheticGreen Fluorescent ProteinsHumans

Substanzen

Rabies VaccinesAntibodies, ViralAntibodies, NeutralizingViral Envelope ProteinsGlycoproteinsAntigens, Viralglycoprotein G, Rabies virusVaccines, SyntheticGreen Fluorescent Proteins

Autor:innen und Institutionen

  • South China Institute of Biomedicine, Guangzhou, Guangdong, China.
  • School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.

ORCID-Profile: Hongyan Du

Förderung

  • Guangdong Basic and Applied Basic Research Foundation
  • Natural Science Foundation of Guangdong Province
  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Shuai, L., Xu, M., Pei, N., Zhu, C., Belghait, M., Hu, Z., Li, J., Li, H., Mao, Y., & Du, H. (2025). Novel rabies vaccine candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein. PLOS Neglected Tropical Diseases, 19(8), e0013404. https://doi.org/10.1371/journal.pntd.0013404

Vancouver

Shuai L, Xu M, Pei N, Zhu C, Belghait M, Hu Z, et al. Novel rabies vaccine candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein. PLOS Neglected Tropical Diseases. 2025;19(8):e0013404. doi:10.1371/journal.pntd.0013404

BibTeX
@article{Shuai2025,
  author = {Shuai, Lifang and Xu, Mingyu and Pei, Nana and Zhu, Cheng and Belghait, Marwa and Hu, Zhiming and Li, Jinlong and Li, Hongwei and Mao, Yingying and Du, Hongyan},
  title = {Novel rabies vaccine candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  volume = {19},
  number = {8},
  pages = {e0013404},
  doi = {10.1371/journal.pntd.0013404}
}
Kostenlos starten →